RNA Modification Loss in Mitochondria Triggers Epithelial Autoimmune Inflammation

Understanding why the body's own tissues become targets in autoimmune disease has long eluded researchers, and most mechanistic work has focused on immune cells rather than the epithelial barriers that first sense and broadcast danger signals. This PNAS study repositions epithelial cells as active instigators of chronic inflammation — not merely bystanders — through a previously unappreciated RNA-level control mechanism.

The research identifies a specific epitranscriptomic checkpoint involving chemical modifications to mitochondrial RNA (mtRNA). When this surveillance system is compromised, unmodified or aberrant mtRNA accumulates and escapes into the cytoplasm, where innate immune sensors misread it as foreign genetic material. That misidentification triggers sustained type I interferon (IFN-I) signaling — the same cytokine cascade implicated in lupus, Sjögren's syndrome, and related systemic autoimmune conditions. The epithelial origin of this IFN-I burst distinguishes the finding from models centered on plasmacytoid dendritic cells or hematopoietic lineages.

This work sits at the intersection of two rapidly evolving fields: epitranscriptomics — the study of reversible RNA chemical marks such as m6A and pseudouridine — and innate immune sensing of endogenous nucleic acids. The idea that mitochondria can become sources of immunostimulatory RNA is not entirely new; mtDNA release has been linked to STING pathway activation in senescent cells and in lupus nephritis. What is novel here is the RNA-level surveillance angle and the specific epithelial compartment involved. The finding raises important questions about whether epitranscriptomic enzyme deficiencies are heritable risk factors in autoimmune-prone families, and whether pharmacological restoration of RNA modification activity could dampen IFN-I signaling without broadly suppressing immunity. As a mechanistic study, causal claims in humans remain to be established, but the pathway it illuminates is therapeutically tractable and conceptually significant for IFN-driven autoimmune disease.